Heterozygous loss-of-function (LoF) variants in ATM are associated with approximately 2-fold increased lifetime risks for breast cancer (MIM#114480) with a penetrance of 20-30%; and a 6.5-fold increased risk for pancreatic cancer 7-11. This evidence concerns the gene ATM and breast carcinoma.